ENSC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ensysce Biosciences Inc (ENSC) is not a strong buy for a beginner, long-term investor at this time. While the company has shown some revenue growth, its financial performance remains weak with negative net income, declining EPS, and no gross margin. Technical indicators are neutral, and there are no significant positive catalysts or trading signals to support an immediate buy decision. The stock is better suited for monitoring rather than immediate investment.
The MACD is positive and expanding, indicating slight bullish momentum. RSI is in the neutral zone at 70.823, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level (R1: 0.598), which could act as a barrier to further price increases.
The company reported a Q4 GAAP EPS beat by $0.51 and a 44.39% YoY increase in revenue. Cash and cash equivalents increased to $4.3 million, providing some financial stability.
Additionally, there are no significant hedge fund or insider trading trends, and no recent congress trading data is available.
In Q4 2025, revenue increased by 44.39% YoY to $1,882,336. However, net income dropped to -$2,767,648 (-22.35% YoY), EPS fell to -$0.74 (-74.39% YoY), and gross margin dropped to 0 (-100% YoY). Despite revenue growth, the company's profitability metrics remain weak.
No recent analyst ratings or price target updates are available for ENSC.
